Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Introduction: Historically, renal cell carcinoma (RCC) is considered a chemotherapy-resistant tumor. The cornerstone of systemic therapy included mammalian target of rapamycin (mTOR) inhibitors, endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitors (TKIs). Currently, a new era is...
| Publicado en: | Expert Review of Anticancer Therapy Vol. 17; no. 4; pp. 357 - 369 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Apr2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121963434&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 121963434 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14737140 1IHQ jtl: Expert Review of Anticancer Therapy issn: 14737140 maglogo: N pubinfo: dt: Apr2017 vid: 17 iid: 4 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 121963434 121963434 NLM28162024 121963434 10.1080/14737140.2017.1292138 NLM28162024 121963434 ppf: 357 ppct: 12 formats: tig: atl: Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go? aug: au: Anselmo Da Costa, Inês Rausch, Steffen Kruck, Stephan Todenhöfer, Tilman Stenzl, Arnulf Bedke, Jens Anselmo da Costa, Inês Todenhöfer, Tilman affil: Department of Urology, Eberhard Karls University, Tuebingen, Germany sug: subj: Kidney Neoplasms Therapy Immunotherapy Methods Carcinoma, Renal Cell Therapy Kidney Neoplasms Pathology Patient Selection Cancer Vaccines Immunology Carcinoma, Renal Cell Pathology Kidney Neoplasms Immunology Algorithms Cancer Vaccines Administration and Dosage Carcinoma, Renal Cell Immunology Immunotherapy Adverse Effects ab: Introduction: Historically, renal cell carcinoma (RCC) is considered a chemotherapy-resistant tumor. The cornerstone of systemic therapy included mammalian target of rapamycin (mTOR) inhibitors, endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitors (TKIs). Currently, a new era is enteres with promising immunotherapeutic treatments, which are becoming commercially available. Areas covered: We provide a comprehensive review using PubMed and ClinicalTrials.gov about the following immunotherapies in RCC: i) vaccine therapy, ii) adoptive T Cell Transfer and CAR T cells, iii) nonspecific immunotherapy - IL-2 (new formulations), iv) Checkpoint inhibitors, v) other checkpoint-molecules. We will also discuss their mechanism of action and toxicity, the importance of developing new patient selection algorithms (immunoprofiling, guidelines updates) and new biomarkers such as PD-1 expression. Expert commentary: Immunotherapy shows promise, and the current tools used in clinical practice, including guidelines, staging-classification and algorithms should be revised and adapted to the new immunotherapeutic drugs. Although immunotherapy in RCC show promising results, more research is needed in parallel to discover biomarkers that enable the prediction of a treatment response and therefore lead to better patient selection. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|